OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Updates in the Treatment of Waldenström Macroglobulinemia

home / scientific-interchange-and-workshop / updates-in-the-treatment-of-waldenstr-m-macroglobulinemia
Updates in the Treatment of Waldenström Macroglobulinemia

EP. 1: Updates in the Treatment of Waldenström Macroglobulinemia

August 13th 2021

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Sikander Ailawadhi, MD

EP. 2: Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

By Sikander Ailawadhi, MD
September 3rd 2021

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

Jorge J. Castillo, MD

EP. 3: Dr. Castillo on the Integration of BTK Inhibitors in Waldenström

By Jorge J. Castillo, MD
September 3rd 2021

Jorge J. Castillo, MD, discusses the integration of BTK inhibitors in Waldenström macroglobulinemia.

Latest Conference Coverage

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact